Zurich, Switzerland
The next Joint Annual Meeting of the Austrian and Swiss Societies of Pathology will take place from 26 (Thursday) to 28 (Saturday) September 2024 in Feldkirch, Austria, with a focus on diagnostic standards and the implementation of new techniques.
Navignostics is delighted to be present at this conference to unveil its plans to bring multiplexed imaging into routine clinical applications.
Spatially resolved single-cell proteomics for treatment response prediction in metastatic colorectal cancer
Dr. Benjamin Ehret
Thursday Sep. 26, 15:35-15:45
Colorectal cancer (CRC) is the fourth leading cause of cancer death globally. Around 50% of patients develop metastatic CRC (mCRC), with a 5-year survival rate of ~14%. Choosing the best first-line therapy is crucial, but no biomarkers exist to predict patient response. Therefore, new diagnostic strategies are urgently needed to capture mCRC heterogeneity and predict individual treatment response.
To tackle this, we created a cohort of 400 mCRC patients with tissue samples and treatment/response data. We used spatial single-cell proteomics and developed two 40-plex antibody panels for imaging mass cytometry (IMC) to study tumor and immune compartments. Tissue microarrays and multiplexed images were analyzed using a computational pipeline to identify biomarkers distinguishing responders from non-responders.
Preliminary results show that our approach can identify features linked to therapy response, such as single-cell marker expression and spatial cell interactions. These findings will be extended in larger mCRC cohorts and validated in future prospective studies to help clinicians better tailor treatments for mCRC patients.
Spatial single cell proteomics to facilitate the treatment decision process in the clinics
Dr. Stéphane Chevrier (in replacement for Dr. med. Simon Haefliger)
Saturday Sep. 28, 9:30-10:00
Navignostics was founded in 2022 as a spin-off from the University of Zurich Bodenmiller Lab with the aim of combining highly multiplex tumor imaging with advanced data analytics to enable personalized treatment decisions for cancer patients.
With growing numbers of available cancer drugs, it becomes increasingly challenging for clinicians to identify the most appropriate treatment for each cancer patient. Navignostics complements standard pathology and next-generation sequencing approaches with additional layers of information through highly multiplex imaging based on 40plex antibody panels. Navignostics’ approach enables a precise mapping of the cell types present in the tissue, including their frequencies and spatial organisation, as well as an in-depth characterization of their marker expression profile, covering a large number of direct drug targets.
Navignostics is actively engaging with biotech/pharma and clinical partners to address specific clinical questions and to identify novel biomarkers for drug response and drug mode of action. In addition, Navignostics is developing a first-of-its-kind inhouse IVD test to provide treatment decision support for beyond-standard-care patients with lung or colorectal cancer based on a single FFPE tissue section.
